First-in-human phase I dose escalation study of MK-8033 in patients with advanced solid tumors

@article{Keedy2018FirstinhumanPI,
  title={First-in-human phase I dose escalation study of MK-8033 in patients with advanced solid tumors},
  author={Vicki Leigh Keedy and H. P. Lenz and Leonard B. Saltz and Jennifer G. Whisenant and Jordan D. Berlin and Luis H Camacho},
  journal={Investigational New Drugs},
  year={2018},
  volume={36},
  pages={860-868}
}
Background C-Met, which is frequently activated in multiple cancers, has been implicated in tumor formation, progression, metastasis, angiogenesis, and resistance to multiple therapies. MK-8033 is a small-molecule inhibitor of c-Met that binds preferentially to the activated conformation, and has demonstrated anti-tumor activity in preclinical models. This first-in-human trial was performed to establish the safety and maximum tolerated dose (MTD), as well as preliminary pharmacokinetics (PK… CONTINUE READING